Stereotaxis, Inc. · AMEX:STXS
Stereotaxis — Investor Presentation (September 2010)
19 slides from Stereotaxis's investor presentation, Sep 28, 2010
Slide 1: Exhibit 99.1
NASDAQ: STXS Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements During the course of this presentation, the Company may make projections and other forward- looking statements regarding future events or the future financial performance of the Company, including without limitation, statements regarding future operating results, growth op
Slide 3: Investment Considerations
Investment Considerations Two innovative technology platforms: Niobe ® Magnetic Navigation System Odyssey ™ Enterprise Solutions Substantial IP portfolio Large, fast growing (+20%) cardiology ablation market Poised for continued growth in electrophysiology (EP) Expansion into new markets New geograp
Slide 4: Niobe Magnetic Navigation System
Niobe Magnetic Navigation System Magnet-guided catheter distal tip provides precise remote control of therapeutic devices.
Slide 5: Niobe Provides Precision and Safety
Niobe Provides Precision and Safety Precise control of catheter distal tip provides: Effective lesion creation through constant contact Exceptional mapping capability Exemplary safety Proven in all chambers of the heart
Slide 6: Niobe's Advantages vs. Manual
Manual Niobe Physician Efficacy Safety Efficiency In procedure room exposed to fluoroscopy Physician: Significant X-ray exposure Patient: Major event rate ~2.8% Higher variability in procedure times In control room outside fluoroscopy field Clearly better in several applications - VT, pediatrics, co
Slide 7: Strong Clinical Validation
Atrial Fibrillation 30 Publications Up to 100% acute success Improved chronic outcomes Pediatric Arrhythmia 5 publications 93% acute success Low fluoro, no complications Congenital Heart 6 publications 90% success rate “As easy as normal adults” Ventricular Tachycardia 13 publications Up to 100% acu
Slide 8: Major Advantages in Ventricular Tachycardia Ablation
Major Advantages in Ventricular Tachycardia Ablation 97% 24% 81% 28% Acute Success (%) Recurrence (%) Case Time (min) Fluoro Time (min) RF Apps STXS Manual p = 0.03 p < 0.01 p < 0.001 NS NS • VT is an abnormally fast heart rhythm that originates from one of the ventricles and can lead to potentially
Slide 9: Global EP Market is Large and Growing
Global EP Market is Large and Growing Source: Millennium Research Group (2009); Stereotaxis internal analysis EP Procedures Routine AF VT Other Total Complex Prevalence Annual Procedures Annual Growth >20M >10M >3M >5M >18M 170K 100K 30K 40K 170K <10% 25% 15% 15% 20% Stereotaxis focused on complex a
Slide 10: Niobe Market Adoption & Procedure Growth
Niobe Market Adoption & Procedure Growth 30,000 + procedures Cumulative Procedures Growing Worldwide Penetration 141 Systems Installed 60% US - 40% OUS Canada - United States - Europe - Saudi Arabia - Russia - China - Korea - Japan - Singapore - Taiwan - Australia -
Slide 11: Odyssey Enterprise Solutions
Odyssey Enterprise TM Solutions Odyssey Vision Integrates and centralizes all EP lab related information to significantly enhance physicians’ efficiency
Slide 12: The Odyssey Product Line
The Odyssey Product Line 140 Niobe Labs CONNECT CINEMA VISION Efficiently integrate data and control during procedures Standardize all labs to increase staff effectiveness Drive world-class practices by capturing, compressing and recording data for storage and networking NIOBE Accelerate clinical ed
Slide 13: Business Model
Business Model Capital Revenue Recurring Revenue Niobe Odyssey Workstation Odyssey Cinema • 141 Niobe systems installed • 2,500 EP labs worldwide • 20+% growth; ~60% margin • 25% growth (YTD 2010 vs. 2009) • 80% margin Capital Driven • Technical service • Software license Niobe Utilization • Stereot
Slide 14: Strategies to Accelerate Growth
Strategies to Accelerate Growth
Slide 15: Stereotaxis Financial Update
$0.0 $4.0 $8.0 $12.0 $16.0 Q1 Q2 Q3 Q4 $11.2 $8.8 $7.2 $7.3 $5.0 $10.2 $12.4 $6.3 $11.2 $7.7 New Orders to Backlog Revenue Momentum Recurring Revenue $ millions $ millions $0 $2 $4 $6 $8 $10 $12 $14 $16 Q1 Q2 Q3 Q4 $7.0 $11.1 $10.6 $10.7 $12.6 $15.0 $10.6 $13.3 $12.1 $14.1 $ millions Stereotaxis Fin
Slide 16: Stereotaxis Financial Update
$0.0 $4.0 $8.0 $12.0 Q1 Q2 Q3 Q4 Total Inventory -$20.0 -$15.0 -$10.0 -$5.0 $0.0 $5.0 Q1 Q2 Q3 Q4 Cash Flow (Burn) $0.0 $5.0 $10.0 $15.0 $20.0 $25.0 Q1 Q2 Q3 Q4 Operating Expenses 55.0% 60.0% 65.0% 70.0% 75.0% Q1 Q2 Q3 Q4 Gross Margin Percentage $ millions $ millions $ millions 65.5% 68.9% 72.5% 60.
Slide 17: Liquidity
$3.0 $1.3 $3.6 Liquidity $0 $2 $4 $6 $8 $10 Operating Cash Flow Ex A/R BWI Debt Accounts Receivable Q2 2010 Cash Burn Analysis $ Millions $7.9 $ Millions * Cash burn includes repayment of Biosense Webster advance.
Slide 18: Investment Considerations
Investment Considerations Two innovative technology platforms: Niobe ® Magnetic Navigation System Odyssey ™ Enterprise Solutions Substantial IP portfolio Large, fast growing (+20%) cardiology ablation market Poised for continued growth in electrophysiology (EP) Expansion into new markets New geograp
Slide 19: Q & A
Q & A